TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an announcement.
ResMed Inc. has reported changes in the beneficial ownership of its common stock by its Chairman and CEO, Michael J. Farrell. The report indicates that performance-based restricted stock units granted in 2022 were earned, and a portion of these shares was disposed of to cover tax obligations. This transaction reflects the company’s ongoing commitment to aligning executive compensation with performance metrics, potentially impacting investor perceptions and stakeholder confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of equipment related to sleep disorders, respiratory care, and connected health solutions. The company is known for its innovative products that cater to patients with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases, aiming to improve patient outcomes and enhance quality of life.
Average Trading Volume: 1,214,271
Technical Sentiment Signal: Buy
Current Market Cap: A$56.69B
For a thorough assessment of RMD stock, go to TipRanks’ Stock Analysis page.